<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
	<title>Avalon</title>
   <meta name="description" content="">
   <meta name="author" content="">
   <!--#include virtual="./common/static.html"-->
	
</head>
<body>
	<!--#include virtual="./common/header.html"-->
	<div class="main-wrapper ">
		<div class="white-wrapper pb30">
			<h3 class="ti-bar" id="MISSIONVISION">MISSION & VISION</h3>
			<ul class="ul-ioc radius">
				<li>A premiere <b>healthcare management provider & biotechnology developer</b></li>
				<li>Dedicated to <b>integrating & managing global healthcare resources</b></li>
				<li>Empowering <b>high-impact biomedical innovations</b></li>
				<li>Engaging in <b>bio-venture investment</b></li>
			</ul>	
			<h3 class="pt50"></h3>
		</div>

		<div class="white-wrapper  ">
			<h3 class="ti-bar" id="CORPORATEHEADQUARTERS">CORPORATE HEADQUARTERS </h3>
			<div class="about-use-big-img "  >
				 <!-- <img   src="../static/imgs/@contact-us-3.jpg"> -->
			</div>	
		</div>

		<div class="gray-wrapper pb50">
			<h3 class="ti-bar" id="CORPORATEOVERVIEW">CORPORATE OVERVIEW</h3>
			<div class="article-wrapper w624">
				<div class="fc img-text">
					<p >
						Avalon GloboCare Corp. (OTCQB : AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab."
					</p>
					<img class="fr" src="../static/imgs/image009.png">
				</div>
				<br>
				<p>
					In addition, AVCO provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. AVCO, via its subsidiary “Avalon RT9 Properties, LLC”, also engages in the acquirement and management of healthcare facility.
				</p>
				<br>
				<p>
					Through its U.S. subsidiary, GenExosome Technologies Inc., AVCO further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.
				</p>
				<br>
			</div>	
		</div>
		<div class="white-wrapper pb30">
			<h3 class="ti-bar"  id="MANAGEMENT">MANAGEMENT</h3>
			<div class="down-article-list">
				<div class="one">
					<div class="name">David Jin, M.D., Ph.D.  </div>
					<div class="chirf toggle-btn">Chief Executive Officer, Co-founder  </div>
					<div class="article">
						<p>
							David Jin, MD, Ph.D., a director and Chief Executive Officer of the Company and AHS. <br> <br> 
	
							From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology.<br> <br> 

							Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.<br> <br> 

							Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters.<br> <br> 

							Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology.<br> <br> 

							Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Meng Li  </div>
					<div class="chirf toggle-btn">Chief Operating Officer  </div>
					<div class="article">
						<p>
							Meng Li is Chief Operating Officer, Secretary and a member of the Board of Directors. <br><br>

							Ms. Li has over 15 years of executive experience in international marketing, branding, communication, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenithmedia (a Publicis Group company) from 2000-2006 as Senior Manager. <br><br>

							Ms. Li received a Bachelor of Arts in International Economic Law from University of Dalian Maritime University, China.
 
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Luisa Ingargiola    </div>
					<div class="chirf toggle-btn">Chief Financial Officer  </div>
					<div class="article">
						<p>
							Luisa Ingargiola graduated in 1989 from Boston University with a Bachelor Degree in Business Administration and a concentration in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida.
							<br><br>
							In 1990, Ms. Ingargiola joined Boston Capital Partners as an Investment Advisor in their Real Estate Limited Partnership Division. In this capacity, she worked with investors and partners to report investment results, file tax forms, and recommend investments. In 1992, Ms. Ingargiola joined MetLife Insurance Company as a Budget and Expense Manager. In this capacity she managed a $30 million dollar annual budget. Her responsibilities included budget implementation, expense and variance analysis and financial reporting. From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer at MagneGas Corporation (Nasdaq: MNGA) and continues to serve as a director.
							<br><br>
							Ms. Ingargiola has served as Audit Chair and Board Director for several public and private companies.  She currently serves as Audit Chair of FTE Networks, Inc (NYSE:FTNW) and Electra Mecchanica (OTC:ECCTF).
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Steven P. Sukel    </div>
					<div class="chirf toggle-btn">President, Avalon RT9 Properties, LLC </div>
					<div class="article">
						<p>
							Steven P. Sukel is a licensed as an attorney in New Jersey who currently analyzes real estate investment opportunities and operates and manages commercial properties. <br><br>

							Mr. Sukel has extensive business experience and was formerly associated with Ernst & Young prior to establishing his own law practice.<br><br>

							Mr. Sukel has focused on New Jersey, multi-state and local taxation and real estate law since 1990 in both public and private practice. Mr. Sukel was with Ernst & Young’s State & Local Tax practice, served as the New Jersey Liaison between the New Jersey Bar Association Taxation Section and the New Jersey CPA Society, was a Past Chair of the New Jersey Bar Association Taxation Section and served two terms on the New Jersey Supreme Court Committee on the Tax Court.
							<br><br>
							Mr. Sukel received his BA from the University of Scranton and J.D from Quinnipiac University School of Law.
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Bo Chen, Ph.D.   </div>
					<div class="chirf toggle-btn">Vice President of Mergers & Acquisitions</div>
					<div class="article">
						<p>
							Bo Chen,Ph.D. was one of the original founders of the Ludaopei Hospital Group in China, and has served as the global business development director for the past 5 years. The Ludaopei Hospital Group is one of the fastest growing private medical companies in China presently, consisting of multiple hospitals and research centers specialized in leukemia and cell therapeutics. Prior to joining the Ludaopei Hospital Group Dr. Chen had multiple leadership positions in healthcare and biotechnology industries. <br>	<br>	

							Dr. Chen holds a Ph.D. degree in engineering science from Virginia Tech.
						</p>
					</div>
				</div>
			</div> 
		</div>
		<div class="gray-wrapper pb30">
			<h3 class="ti-bar" id="BOARDOFDIRECTORS">BOARD OF DIRECTORS</h3>
			<div class="down-article-list">
				<div class="one">
					<div class="name">Daniel Lu  </div>
					<div class="chirf toggle-btn">Chairman of the Board  </div>
					<div class="article">
						<p>
							Daniel Lu is Chairman of the Board of the Company and AHS.<br><br>

    						Mr. Lu is a seasoned healthcare entrepreneur with extensive operation in China. He has been serving as Chairman of the Board for the DaoPei Medical Group (“DPMG”) since 2010. Under his leadership, DPMG has recently expanded its clinical network involving a state-of-the-art stem cell bank at Wuhan Biolake, three top-ranked private hospitals (located in Beijing, Shanghai, and Hebei), specialty hematology laboratories, as well as a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and member of the Academy of Engineering in China. <br><br>	
							Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. Prior to joining DPMG, Mr. Lu served as Chief Operating Officer for BioTime Asia Limited which is a subsidiary of BioTime, Inc. (NYSE/AMEX:BTX) in 2009. 
						</p>
					</div>
				</div>

				<div class="one">
					<div class="name">David Jin, MD, Ph.D.  </div>
					<div class="chirf toggle-btn">Director  </div>
					<div class="article">
						<p>
						David Jin, MD, Ph.D., a director and Chief Executive Officer of the Company and AHS.
						 <br>	<br>					
						From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology.<br>	<br>

		 

						Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.<br>	<br>

		 

						Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters.<br>	<br>

		 

						Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology.<br>	<br>

		 

						Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.
  
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Congressman Billy Tauzin    </div>
					<div class="chirf toggle-btn">Director  </div>
					<div class="article">
						<p>
						 Congressman Tauzin has a long and distinguished 36-year elective career culminating in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives, which oversees food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.  <br><br>	

						After leaving Congress in 2005, Congressman Tauzin was invited to become the President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he oversaw their participation in putting together the Partnership for Prescription Assistance, which has provided free and nearly free medication for over 10 million patients.<br><br>	

						Congressman Tauzin now serves on the Boards of Directors of Entergy Corporation, LHC Group, the Alliance for Aging Research, Lenitiv Scientific, CaptureRx, and Resilient Network Systems, Inc. In 2010, he founded Tauzin Strategic Networks and co-founded Tauzin Consultants, LLC, a DC-based government relations, advocacy and strategic counsel organizations, fostering innovative solutions to some of the world's biggest challenges.
  
						</p>
					</div>
				</div>

				<div class="one">
					<div class="name">Tevi Troy  </div>
					<div class="chirf toggle-btn">Director  </div>
					<div class="article">
						<p>
						Dr. Troy currently serves as Vice President of Public Policy for Juul Labs. He brings extensive senior level government and industry experience having served the White House in several high-level positions, including Deputy Secretary of the U.S. Department of Health and Human Services (HHS), as well as Deputy Assistant and then Acting Assistant to the President for Domestic Policy. As Deputy Secretary of HHS, Dr. Troy oversaw the largest civilian department in the federal government, with a budget of $716 billion and over 67,000 employees. From 2014 to 2018, Dr. Troy was the founder and CEO of the American Health Policy Institute. He also served as a Senior Fellow at Hudson Institute, where he remains an Adjunct Fellow, and was a researcher at the American Enterprise Institute. From 1998 to 2000, Dr. Troy served as the Policy Director for Senator John Ashcroft. From 1996 to 1998, Troy was Senior Domestic Policy Adviser and later Domestic Policy Director for the House Policy Committee, chaired by Congressman Christopher Cox. <br> <br>

 

						Dr. Troy's other affiliations include: contributing editor for Washingtonian magazine; member of the publication committee of National Affairs; member of the Board of Fellows of the Jewish Policy Center; member of the Board of Directors of R Street; a Senior Fellow at the Potomac Institute; and a member of the Blue Ribbon Study Panel examining the United States’ readiness to address bioterrorism and naturally occurring outbreaks. In 2012, he was a Special Policy Adviser to the Mitt Romney presidential campaign and served as Director of Domestic Policy for the nascent Romney transition. Dr. Troy has a B.S. in Industrial and Labor Relations from Cornell University and an M.A and Ph.D. in American Civilization from the University of Texas at Austin. <br>
  			
						</p>
					</div>
				</div>

				<div class="one">
					<div class="name">Meng Li    </div>
					<div class="chirf toggle-btn">Director  </div>
					<div class="article">
						<p>
						 Meng Li is Chief Operating Officer, Secretary and a member of the Board of Directors. <br>	 <br>	 

						Ms. Li has over 15 years of executive experience in international marketing, branding, communication, and media investment consultancy. Ms. Li served as Managing Director at Maxus / GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenithmedia (a Publicis Group company) from 2000-2006 as Senior Manager. <br>	 <br>	
 
						Ms. Li received a Bachelor of Arts in International Economic Law from University of Dalian Maritime University, China.
  
						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Steven P. Sukel    </div>
					<div class="chirf toggle-btn">President, Avalon RT9 Properties, LLC  </div>
					<div class="article">
						<p>
						Steven P. Sukel is a licensed as an attorney in New Jersey who currently analyzes real estate investment opportunities and operates and manages commercial properties.  <br><br>	

						Mr. Sukel has extensive business experience and was formerly associated with Ernst & Young prior to establishing his own law practice.   <br><br>	

						Mr. Sukel has focused on New Jersey, multi-state and local taxation and real estate law since 1990 in both public and private practice. Mr. Sukel was with Ernst & Young’s State & Local Tax practice, served as the New Jersey Liaison between the New Jersey Bar Association Taxation Section and the New Jersey CPA Society, was a Past Chair of the New Jersey Bar Association Taxation Section and served two terms on the New Jersey Supreme Court Committee on the Tax Court.   <br><br>	

						Mr. Sukel received his BA from the University of Scranton and J.D from Quinnipiac University School of Law.

						</p>
					</div>
				</div>
				<div class="one">
					<div class="name">Yancen Lu     </div>
					<div class="chirf toggle-btn">Director  </div>
					<div class="article">
						<p>
						Yancen Lu has more than 19 years’ experience in investment banking and equity investment management. <br>	<br>	

						Mr. Lu is Managing Director of FountainVest Partners. Besides his professionalism in securities, investment and capital management, Mr Lu has special focus and comprehensive understanding of the global medical and healthcare industry, he is Director of leading healthcare corporations including Sino Hospital Investment Corporation (Hong Kong), Chang’an Hospital (the largest private hospital in Northwest China), and DIH Medical Technologies.  <br>	<br>	
 
						Mr. Lu received Bachelor and Master degrees of Engineering Economics from Tianjin University.

						</p>
					</div>
				</div>
			</div> 
		</div>
		<div class="white-wrapper pb30 border-btm tac">
			<h3 class="ti-bar" id="CODEOFCONDUCT">CODE OF CONDUCT</h3>
			<a href="http://www.avalon-globocare.com/CodeofConduct.pdf" target="_blank"  class="blank-btn">Avalon GloboCare Code of Conduct</a> 			</div>
	</div>
	<!--#include virtual="./common/footer.html"-->
	<!--#include virtual="./common/script.html"--> 
 
</body>
</html>
